Press Release
Press Release
Press Contacts: Erik Cummins, Matt Hyams, Olivia Thomas
11.21.16
A team of Pillsbury IP lawyers has earned an important victory for IntelGenx Corp., securing a license from Eli Lilly for United States Patent No. 6,943,166—the company’s tadalafil dosing patent.
The firm’s efforts on behalf of IntelGenx before the Patent Trial and Appeal Board enables IntelGenx to commercialize its Tadalafil ED VersaFilm™ product in the U.S. prior to the expiration of the '166 dosing patent (pending FDA approval). With the agreed-to license in hand, Tadalafil ED VersaFilm™ has the potential to be the only film delivery product of the blockbuster ED drug product on the market.
"Securing the license with Lilly is a significant achievement for IntelGenx. It will substantially alleviate any legal concern regarding the launch of our Tadalafil VersaFilm™ product ahead of the expiry of the '166 dosing patent," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "This license opens IntelGenx to the lucrative U.S. ED market and accelerates our partnering of this product for commercializing Tadalafil VersaFilm™ in the U.S. and abroad. We look forward to continuing IntelGenx' transformation into a global leader of pharmaceutical oral films."
The Pillsbury team representing IntelGenx was led by Pillsbury partner H. Keeto Sabharwal, with significant involvement from partners Bryan Collins and Patrick Doody. Associate Michelle Herrera also contributed to the win.
Established in 2003, Montreal-based IntelGenx is a leading oral drug delivery company focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. More information is available about the company at www.intelgenx.com.